Advertisement

Computational assessment on the interaction of amantadine drug with B12N12 and Zn12O12 nanocages and improvement in adsorption behaviors by impurity Al doping

  • Davood Farmanzadeh
  • Masoomeh Keyhanian
Regular Article
  • 8 Downloads

Abstract

In the present research, the interaction between B12N12 and Zn12O12 nanocages and their Al-doped structures with amantadine antiviral drug were examined by employing density functional theory calculations in the gas phase and water environment. Based on the obtained results from adsorption energies (Eads), amantadine drug prefers to approach via its nitrogen atom to the boron and zinc atoms of B12N12 and Zn12O12. In addition, it was found that drug molecule can be adsorbed chemically on the surfaces of pristine nanocages in both gas phase and water media. Toward improvement in the adsorption of amantadine, one of B and Zn atoms of nanocages was substituted by an aluminum atom which leads to increase in Eads values over Al atom in doped nanocages than that of pristine nanocages. Consequently, among these nanocages, it was suggested that Al-doped B12N12 nanocage was the most favorable carrier for amantadine drug delivery because of its desired adsorption energy and sensing ability of drug.

Keywords

Nanocage Amantadine Antiviral Density functional theory Drug delivery 

Notes

Acknowledgements

We sincerely appreciate the financial support of the University of Mazandaran for this scientific research.

References

  1. 1.
    Hawthorne MF (1991) Biochemical applications of boron cluster chemistry. Appl Chem 63:327–334CrossRefGoogle Scholar
  2. 2.
    Sivaev IB, Bregadze VV (2009) Polyhedral boranes for medical applications: current status and perspectives. Eur J Inorg Chem 11:1433–1450CrossRefGoogle Scholar
  3. 3.
    Petranovska AL, Abramov NV, Turanska SP, Gorbyk PP, Kaminskiy AN, Kusyak NV (2015) Adsorption of cis-dichlorodiammineplatinum by nanostructures based on single-domain magnetite. J Nanostruct Chem 5:275–285CrossRefGoogle Scholar
  4. 4.
    Ohta T, Hashida Y, Yamashita F, Hashida M (2016) Development of novel drug and gene delivery carriers composed of single-walled carbon nanotubes and designed peptides with PEGylation. J Pharmaceut Sci 105:2815–2824CrossRefGoogle Scholar
  5. 5.
    Samanta PN, Das KK (2017) Noncovalent interaction assisted fullerene for the transportation of some brain anticancer drugs: a theoretical study. J Mol Graph 72:187–200CrossRefGoogle Scholar
  6. 6.
    Nikfar Z, Shariatinia Z (2017) DFT computational study on the phosphate functionalized SWCNTs as efficient drug delivery systems for anti-osteoporosis zolendronate and risedronate drugs. Phys E 91:41–59CrossRefGoogle Scholar
  7. 7.
    Moradi M, Nouraliei M, Moradi R (2017) Theoretical study on the phenylpropanolamine drug interaction with the pristine, Si and Al doped [60] fullerenes. Phys E 87:186–191CrossRefGoogle Scholar
  8. 8.
    Shakerzadeh E (2017) Quantum chemical assessment of the adsorption behavior of fluorouracil as an anticancer drug on the B36 nanosheet. J Mol Liq 240:682–693CrossRefGoogle Scholar
  9. 9.
    Friedman SH, DeCamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL (1993) Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J Am Chem Soc 115:6506–6509CrossRefGoogle Scholar
  10. 10.
    Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CKF, Luh TY, Choi DW, Lin TS (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci 94:9434–9439CrossRefPubMedGoogle Scholar
  11. 11.
    Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ (1999) In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci 96:5182–5187CrossRefPubMedGoogle Scholar
  12. 12.
    Montellano A, Da RT, Bianco A, Prato M (2011) Fullerene C60 as a multifunctional system for drug and gene delivery. Nanoscale 3:4035–4041CrossRefPubMedGoogle Scholar
  13. 13.
    Andujar SA, Lugli F, Höfinger S, Enriz RD, Zerbetto F (2012) Amyloid-β fibril disruption by C60- molecular guidance for rational drug design. Phys Chem Chem Phys 14:8599–8607CrossRefPubMedGoogle Scholar
  14. 14.
    Ahmed L, Rasulev B, Turabekova M, Leszczynska D, Leszczynski J (2013) Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations. Org Biomol Chem 11:5798–5808CrossRefPubMedGoogle Scholar
  15. 15.
    Gökpek Y, Bilge M, Bilge D, Alver Ö, Parlak C (2017) Adsorption mechanism, structural and electronic properties: 4-Phenylpyridine & undoped or doped (B or Si) C60. J Mol Liq 238:225–228CrossRefGoogle Scholar
  16. 16.
    Bahrami A, Seidi S, Baheri T, Aghamohammadi MA (2013) first-principles study on the adsorption behavior of amphetamine on pristine, P-and Al-doped B12N12 nano-cages. Superlattices Microst 64:265–273CrossRefGoogle Scholar
  17. 17.
    Rad AS, Ayub K (2016) A comparative density functional theory study of guanine chemisorption on Al12N12, Al12P12, B12N12, and B12P12 nano-cages. J Alloys Compd 672:161–169CrossRefGoogle Scholar
  18. 18.
    Javan MB, Soltani A, Lemeski ET, Ahmadi A, Rad SM (2016) Interaction of B12N12 nano-cage with cysteine through various functionalities: a DFT study. Superlattices Microst 100:24–37CrossRefGoogle Scholar
  19. 19.
    Javan MB, Soltani A, Azmoodeh Z, Abdolahi N, Gholami NA (2016) DFT study on the interaction between 5-fluorouracil and B12N12 nanocluster. RSC Adv 6(106):104513–104521CrossRefGoogle Scholar
  20. 20.
    Hazrati MK, Javanshir Z, Bagheri Z (2017) B24N24 fullerene as a carrier for 5-fluorouracil anti-cancer drug delivery: DFT studies. J Mol Graph 77:17–24CrossRefGoogle Scholar
  21. 21.
    Oku T, Nishiwaki A, Narita I (2004) Formation and atomic structure of B12N12 nanocage clusters studied by mass spectrometry and cluster calculation. Sci Technol Adv Mater 5:635–645CrossRefGoogle Scholar
  22. 22.
    Xu S, Zhang M, Zhao Y, Chen B, Zhang J, Sun CC (2006) Stability and property of planar (BN)x clusters. Chem Phys Lett 423:212–214CrossRefGoogle Scholar
  23. 23.
    Wu S, Yuan N, Xu H, Wang X, Schelly ZA (2006) Synthesis and bandgap oscillation of uncapped, ZnO clusters by electroporation of vesicles. Nanotech 17:4713–4718CrossRefGoogle Scholar
  24. 24.
    de Oliveira OV, Pires JM, Neto AC, dos Santos JD (2015) Computational studies of the Ca12O12, Ti12O12, Fe12O12 and Zn12O12 nanocage clusters. Chem Phys Lett 634:25–28CrossRefGoogle Scholar
  25. 25.
    Aslanzadeh S (2016) Transition metal doped ZnO nanoclusters for carbon monoxide detection: DFT studies. J Mol Model 22(7):160CrossRefPubMedGoogle Scholar
  26. 26.
    Omidvar A (2018) Indium-doped and positively charged ZnO nanoclusters: versatile materials for CO detection. Vacuum 147:126–133CrossRefGoogle Scholar
  27. 27.
    Goyal RN, Gupta VK, Bachheti N (2007) Fullerene-C60-modified electrode as a sensitive voltammetric sensor for detection of nandrolone-an anabolic steroid used in doping. Anal Chim Acta 597:82–89CrossRefPubMedGoogle Scholar
  28. 28.
    Hassani F, Tavakol H (2014) A DFT, AIM and NBO study of adsorption and chemical sensing of iodine by S-doped fullerenes. Sens Actuators B Chem 196:624–630CrossRefGoogle Scholar
  29. 29.
    Mahdavifar Z, Poulad M (2014) Theoretical prediction of ozone sensing using pristine and endohedral metalloboron B80 fullerenes. Sens Actuators B Chem 205:26–38CrossRefGoogle Scholar
  30. 30.
    Hazrati MK, Hadipour NL (2016) Adsorption behaviorof 5-fluorouracil on pristine, B-, Si-, and Al-doped C60 fullerenes: a first-principles study. Phys Lett A 380:937–941CrossRefGoogle Scholar
  31. 31.
    Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144(3620):862–863CrossRefPubMedGoogle Scholar
  32. 32.
    Krupp B, Christodoulou C (2001) Fatigue in multiple sclerosis. Curr Neurol Neurosci Reports 1(3):294–298CrossRefGoogle Scholar
  33. 33.
    Hubsher G, Haider M, Okun M (2012) Amantadine The journey from fighting flu to treating Parkinson disease. Neurology 78(14):1096–1099CrossRefPubMedGoogle Scholar
  34. 34.
    Hay A, Wolstenholme A, Skehel J, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4(11):3021–3024CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Fraunfelder F, Meyer SM (1990) Amantadine and corneal deposits. Am J Ophthalmol 110(1):96–97CrossRefPubMedGoogle Scholar
  36. 36.
    Hughes B, Feiz V, Flynn SB, Brodsky MC (2004) Reversible amantadine-induced corneal edema in an adolescent. Cornea 23(8):823–824CrossRefPubMedGoogle Scholar
  37. 37.
    Kubo SI, Iwatake A, Ebihara N, Murakami A, Hattori N (2008) Visual impairment in Parkinson’s disease treated with amantadine: case report and review of the literature. Parkinsonism Relat Disord 14(2):166–169CrossRefPubMedGoogle Scholar
  38. 38.
    Blanchard DL (1990) Amantadine caused corneal edema. Cornea 9(2):181CrossRefPubMedGoogle Scholar
  39. 39.
    Lin CC, Cheng CY, Hu PS, Lin CP, Hsu SL (2014) Amantadine-related corneal edema and endothelial cell loss: four case reports. Taiwan J Ophthalmol 4(3):137–140CrossRefGoogle Scholar
  40. 40.
    Parlak C, Alver Ö (2017) A density functional theory investigation on amantadine drug interaction with pristine and B, Al, Si, Ga, Ge doped C60 fullerenes. Chem Phys Lett 678:85–90CrossRefGoogle Scholar
  41. 41.
    Noroozi Z, Rahimi R, Solimannejad MA (2018) computational study for the B30 bowl-like nanostructure as a possible candidate for drug delivery system for amantadine. Comput Theor Chem 1129:9–15CrossRefGoogle Scholar
  42. 42.
    Delley B (1990) An allelectron numerical method for solving the local density functional for polyatomic molecules. J Chem Phys 92:508–518CrossRefGoogle Scholar
  43. 43.
    Delley B (1995) DMol, a standard tool for density functional calculations: review and advances. Theor Comput Chem 2:221–254CrossRefGoogle Scholar
  44. 44.
    Monkhorst HJ, Pack JD (1976) Special Points for Brillouin-Zone Integrations. Phys Rev B 13:5188–5192CrossRefGoogle Scholar
  45. 45.
    Grimme S (2006) Semiempirical GGA-type density functional constructed with a long-range dispersion correction. J Comput Chem 27:1787–1799CrossRefPubMedGoogle Scholar
  46. 46.
    Perdew JP, Burke K, Ernzerhof M (1996) Generalized gradient approximation made simple. Phys Rev Lett 77:3865–3868CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Perdew JP, Chevary JA, Vosko SH, Jackson KA, Pederson MR, Singh DJ, Fiolhais C (1992) Atoms, molecules, solids, and surfaces: applications of the generalized gradient approximation for exchange and correlation. Phys Rev B 46:6671–6687CrossRefGoogle Scholar
  48. 48.
    Benedek NA, Snook IK, Latham K, Yarovsky I (2005) Application of numerical basis sets to hydrogen bonded systems: a density functional theory study. J Chem Phys 122:144102CrossRefPubMedGoogle Scholar
  49. 49.
    Hirshfeld FL (1977) Bonded-atom fragments for describing molecular charge densities. Theor Chim Acta 44(2):129–138CrossRefGoogle Scholar
  50. 50.
    Klamt A (1995) Conductor-like screening model for real solvents: a new approach to the quantitative calculation of solvation phenomena. J Phys Chem 99:2224–2235CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Physical Chemistry, Faculty of ChemistryUniversity of MazandaranBabolsarIran

Personalised recommendations